Literature DB >> 7752010

Bacteriologic failure of amoxicillin-clavulanate in treatment of acute otitis media caused by nontypeable Haemophilus influenzae.

J A Patel1, B Reisner, N Vizirinia, M Owen, T Chonmaitree, V Howie.   

Abstract

OBJECTIVE: To evaluate the rate of bacteriologic failure of amoxicillin-clavulanate in the treatment of acute otitis media (AOM) and to identify the risk factors associated with failure.
METHODS: Ninety-nine subjects (mean age, 21.4 months) with AOM were treated with amoxicillin-clavulanate in two prospective study trials that compared efficacy of two experimental antibiotics with amoxicillin-clavulanate. Tympanocentesis for microbiologic studies was performed in all subjects at enrollment; at 3 to 6 days, during amoxicillin-clavulanate therapy; and at other times when clinically indicated. The subjects were followed up for 1 month. Clinical, bacteriologic, and virologic characteristics of the subjects were analyzed.
RESULTS: Bacteriologic failure of treatment occurred in none of 39 subjects (0%) with Streptococcus pneumoniae, two of 25 (8%) with Moraxella catarrhalis, and 11 of 29 (38%) with nontypeable Haemophilus influenzae (NTHi) infection. The failure rate for NTHi was higher than that for other pathogens (p = 0.0007) and was increased when compared with the preceding study period (p = 0.017). Bacteriologic failure was also associated with clinical failure (p = 0.041). In subjects with AOM caused by NTHi the rates of adequate drug compliance were comparable in both success and failure groups. Antimicrobial susceptibility testing by minimum inhibitory concentration and minimum bactericidal concentration (MIC/MBC) assays showed that amoxicillin-clavulanate resistance was not significantly associated with bacteriologic failure of treatment. However, in two subjects, MIC/MBC of the NTHi isolates during therapy were higher than MIC/MBC of the isolates before therapy; these strains of isolates pretherapy and during therapy were discordant as determined by outer membrane protein analysis. The bacteriologic failure rate was higher in nonwhite boys (p = 0.026) and in subjects with a history of three or more previous episodes of AOM (p = 0.008). Other factors such as age, bilaterality of disease, polymicrobial infection, and biotype pattern of NTHi were not associated with treatment failure. When children with adequate drug compliance were analyzed separately, only those with concomitant viral infection of the nasopharynx or middle ear were found to be at an increased risk of bacteriologic failure of treatment (p = 0.04).
CONCLUSIONS: The bacteriologic failure rate of amoxicillin-clavulanate therapy for AOM caused by NTHi was higher in the current study period than in the preceding period. Factors contributing to treatment failure were race, gender, proneness to otitis, and concomitant viral infection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7752010     DOI: 10.1016/s0022-3476(95)70415-9

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  13 in total

Review 1.  New formulations of amoxicillin/clavulanic acid: a pharmacokinetic and pharmacodynamic review.

Authors:  Amparo Sánchez Navarro
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Can the choice of antibiotics for therapy of acute otitis media be logical?

Authors:  R Dagan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-01       Impact factor: 3.267

3.  The other siblings: respiratory infections caused by Moraxella catarrhalis and Haemophilus influenzae.

Authors:  Larry Lutwick; Laila Fernandes
Journal:  Curr Infect Dis Rep       Date:  2006-05       Impact factor: 3.725

4.  Spheroplast-Mediated Carbapenem Tolerance in Gram-Negative Pathogens.

Authors:  Trevor Cross; Brett Ransegnola; Jung-Ho Shin; Anna Weaver; Kathy Fauntleroy; Michael S VanNieuwenhze; Lars F Westblade; Tobias Dörr
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

Review 5.  Moraxella catarrhalis: from emerging to established pathogen.

Authors:  Cees M Verduin; Cees Hol; André Fleer; Hans van Dijk; Alex van Belkum
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

6.  Characterization and evaluation of the Moraxella catarrhalis oligopeptide permease A as a mucosal vaccine antigen.

Authors:  Min Yang; Antoinette Johnson; Timothy F Murphy
Journal:  Infect Immun       Date:  2010-12-06       Impact factor: 3.441

7.  Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children.

Authors:  R Dagan; E Leibovitz; D M Fliss; A Leiberman; M R Jacobs; W Craig; P Yagupsky
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

8.  Clinical potential of engineered cationic antimicrobial peptides against drug resistant biofilms.

Authors:  Jeffrey A Melvin; Ronald C Montelaro; Jennifer M Bomberger
Journal:  Expert Rev Anti Infect Ther       Date:  2016-09-22       Impact factor: 5.091

Review 9.  Viral otitis media.

Authors:  Craig A Buchman; George M Brinson
Journal:  Curr Allergy Asthma Rep       Date:  2003-07       Impact factor: 4.806

Review 10.  Immunopathogenesis of polymicrobial otitis media.

Authors:  Lauren O Bakaletz
Journal:  J Leukoc Biol       Date:  2009-10-20       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.